Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...